Biotech

Shift Bioscience says better benchmarking could make AI “virtual cells” more useful for finding ageing drug targets

A new Nature Biotechnology paper argues that some genetic perturbation models were judged with poorly calibrated metrics, and the Cambridge company plans to use its fix to screen for rejuvenation and fibrosis targets.

Houdini Bio: tackling the gene-silencing barrier in genetic medicines

Cambridge biotech Houdini Bio is developing AI-powered DNA engineering technology designed to help genetic medicines remain active for longer, with a new collaboration with CureAge Therapeutics putting its approach to work in non-viral DNA medicines for peripheral nerve disease.

Big Picture Bio launches with £2.2m to develop AI-designed cancer combination therapies

London biotech Big Picture Bio launches with £2.2m to develop AI-designed cancer combination therapies using a generative world model and wet-lab validation.

Fuse Diagnostics raises £1m to scale rapid molecular testing platform

Cambridge-based diagnostics company Fuse Diagnostics has secured £1 million in new funding to accelerate the commercialisation of its rapid, instrument-free molecular testing platform and expand manufacturing capacity in the UK.

Oxford and 2U Launch New Programme in AI-Driven Drug Discovery

Six-week executive education programme will train scientists and R&D professionals to apply AI across the drug discovery pipeline.

Andelyn to Scale Manufacturing for Genprex’s Diabetes Gene Therapy Programme

AAV-based therapy targeting pancreatic cells moves towards IND-enabling studies and future clinical manufacturing.